Description: Acrux Limited is a drug development company. The Company is engaged in developing and commercializing branded and generic transdermal and topical pharmaceuticals for global markets. The Company's transdermal or topical pharmaceutical product portfolio can be segregated into approximately two streams, such as generic pharmaceutical products and specialty pharmaceutical products. The Company's products include Axiron, Ellavie, Evamist and Lenzetto. Axiron (testosterone) topical solution CIII is a testosterone topical solution approved for application via an armpit (underarm) applicator. It has developed the estradiol spray for women, used to treat moderate to severe hot flushes commonly associated with menopause. In the United States, the Company's estradiol spray is branded Evamist. The Company has licensed its estradiol product to Gedeon Richter to commercialize in various territories, including Europe and Eurasia. Gedeon Richter has branded the estradiol spray as Lenzetto.
Home Page: www.acrux.com.au
ACR Technical Analysis
103-113, Stanley Street
West Melbourne,
VIC
3003
Australia
Phone:
61 3 8379 0100
Officers
| Name | Title |
|---|---|
| Mr. Michael John Kotsanis B.Sc., BSc, GradDipBus, MBus | CEO, MD & Exec. Director |
| Ms. Joanna Johnson B.E., BEc, ICAA | CFO & Company Sec. |
| Ms. Felicia Colagrande B.Sc., BSc (Hons), M.B.A., MBA | Product Devel. & Technical Affairs Director |
| Mr. Charles O'Sullivan B. Pharm | Portfolio Director |
| Mr. Mark Hyman | Project & Technical Devel. Director |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.2685 |
| Price-to-Sales TTM: | 11.9955 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |